Investigational drug · Phase 2
OsrhCT
Also called: Recombinant Human Chymotrypsin 4000U
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric Mucosal Lesion.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "OsrhCT"
First trial start
2024
Dec 19, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OsrhCT", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Mucosal Lesion
Approved drugs for the same conditions: Stomach and esophageal cancer
Largest trials
Live from ClinicalTrials.gov: studies naming "OsrhCT" as an intervention, largest first.
- Efficacy and Safety of OsrhCT and Dimethicone Emulsion Before Upper Endoscopy on Visualization of the Gastric Mucosa.Pivotal-lookingActive, not recruiting
Healthgen Biotechnology Corp.Industry
NCT06722664 · 336 participants (planned) · Start Dec 19, 2024 · Primary completion May 15, 2025
Drug: Recombinant Human Chymotrypsin(OsrhCT) 4000U; Placebo for Recombinant Human Chymotrypsin(OsrhCT) and 1 more · For: Gastric Mucosal Lesion
Sites: Beijing, China; Wuhan, China; Hohhot, China · 5 sites in all
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of OsrhCT in Patients With PleurisyStatus unknown
Healthgen Biotechnology Corp.Industry
NCT06525272 · 72 participants (planned) · Start Jul 2024 · Primary completion Jul 2025
Drug: Recombinant Human Chymotrypsin(OsrhCT); Placebo for Recombinant Human Chymotrypsin(OsrhCT) · For: Pleurisy
Sites: Hefei, China; Shenzhen, China; Wuhan, China · 4 sites in all
- Efficacy and Safety of OsrhCT Before Upper Endoscopy on Improving Visualization of the Gastric Mucosa.Not yet recruiting
Healthgen Biotechnology Corp.Industry
NCT07893600 · 40 participants (planned) · Start Oct 27, 2026 · Primary completion Dec 22, 2026
Drug: Recombinant Human Chymotrypsin(OsrhCT) 4000U; Placebo for Recombinant Human Chymotrypsin(OsrhCT) · For: Gastric Mucosal Lesion
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.